A number of other equities research analysts have also recently commented on CLVS. BidaskClub raised Clovis Oncology from a strong sell rating to a sell rating in a report on Saturday, December 9th. ValuEngine cut Clovis Oncology from a hold rating to a sell rating in a report on Tuesday, December 5th. Morgan Stanley decreased their price target on Clovis Oncology from $89.00 to $86.00 and set an overweight rating on the stock in a report on Thursday, November 2nd. Leerink Swann reissued a buy rating and set a $107.00 price target on shares of Clovis Oncology in a report on Monday, September 18th. Finally, Zacks Investment Research cut Clovis Oncology from a hold rating to a sell rating in a report on Tuesday, October 3rd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the stock. Clovis Oncology currently has an average rating of Buy and an average price target of $91.83.
Clovis Oncology (NASDAQ:CLVS) opened at $65.90 on Wednesday. Clovis Oncology has a twelve month low of $39.83 and a twelve month high of $99.45. The company has a market capitalization of $3,150.19, a price-to-earnings ratio of -7.96 and a beta of 1.39. The company has a quick ratio of 3.16, a current ratio of 3.19 and a debt-to-equity ratio of 0.94.
In other Clovis Oncology news, Director Thorlef Spickschen sold 4,500 shares of the firm’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $60.00, for a total value of $270,000.00. Following the completion of the sale, the director now owns 25,618 shares of the company’s stock, valued at $1,537,080. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $64.16, for a total transaction of $192,480.00. Following the completion of the sale, the insider now directly owns 182,583 shares of the company’s stock, valued at approximately $11,714,525.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,500 shares of company stock valued at $907,200. 12.50% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in CLVS. Capital Analysts LLC bought a new stake in Clovis Oncology in the third quarter worth about $111,000. Phocas Financial Corp. bought a new stake in shares of Clovis Oncology during the second quarter valued at approximately $112,000. Cypress Capital Management LLC WY raised its stake in shares of Clovis Oncology by 272.7% during the third quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock valued at $169,000 after acquiring an additional 1,500 shares in the last quarter. Advisors Asset Management Inc. raised its stake in shares of Clovis Oncology by 160.7% during the second quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 1,168 shares in the last quarter. Finally, Commonwealth Equity Services Inc bought a new stake in shares of Clovis Oncology during the third quarter valued at approximately $239,000.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.com-unik.info/2017/12/24/clovis-oncologys-clvs-hold-rating-reiterated-at-oppenheimer.html.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
What are top analysts saying about Clovis Oncology? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Clovis Oncology and related companies.